Analyzing the Price-to-Earnings Ratio of Vanda Pharmaceuticals Inc (VNDA)

The price-to-earnings ratio for Vanda Pharmaceuticals Inc (NASDAQ: VNDA) is above average at 125.58x. The 36-month beta value for VNDA is also noteworthy at 0.78. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 1 rating it as “sell.”

The public float for VNDA is 54.51M, and at present, short sellers hold a 5.51% of that float. The average trading volume of VNDA on April 03, 2024 was 985.15K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

VNDA) stock’s latest price update

The stock price of Vanda Pharmaceuticals Inc (NASDAQ: VNDA) has jumped by 40.36 compared to previous close of 3.91. Despite this, the company has seen a gain of 42.18% in its stock price over the last five trading days. Market Watch reported 2024-04-02 that Shares of Vanda Pharmaceuticals VNDA, -5.10% jumped 33% to $5.23 in post-market trading after the company said the Food and Drug Administration approved Fanapt to treat manic or mixed episodes associated with bipolar I disorder in adults.

VNDA’s Market Performance

VNDA’s stock has risen by 42.18% in the past week, with a monthly rise of 28.52% and a quarterly rise of 21.42%. The volatility ratio for the week is 3.90% while the volatility levels for the last 30 days are 4.11% for Vanda Pharmaceuticals Inc The simple moving average for the last 20 days is 40.82% for VNDA’s stock, with a simple moving average of 18.35% for the last 200 days.

Analysts’ Opinion of VNDA

Many brokerage firms have already submitted their reports for VNDA stocks, with Jefferies repeating the rating for VNDA by listing it as a “Hold.” The predicted price for VNDA in the upcoming period, according to Jefferies is $12 based on the research report published on February 25, 2022 of the previous year 2022.

BofA Securities, on the other hand, stated in their research note that they expect to see VNDA reach a price target of $22. The rating they have provided for VNDA stocks is “Buy” according to the report published on May 12th, 2021.

Citigroup gave a rating of “Neutral” to VNDA, setting the target price at $14 in the report published on January 14th of the previous year.

VNDA Trading at 37.22% from the 50-Day Moving Average

After a stumble in the market that brought VNDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -21.60% of loss for the given period.

Volatility was left at 4.11%, however, over the last 30 days, the volatility rate increased by 3.90%, as shares surge +30.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +42.61% upper at present.

During the last 5 trading sessions, VNDA rose by +40.03%, which changed the moving average for the period of 200-days by -14.75% in comparison to the 20-day moving average, which settled at $3.96. In addition, Vanda Pharmaceuticals Inc saw 30.05% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at VNDA starting from Polymeropoulos Mihael Hristos, who sale 24,288 shares at the price of $4.13 back on Mar 05 ’24. After this action, Polymeropoulos Mihael Hristos now owns 1,871,730 shares of Vanda Pharmaceuticals Inc, valued at $100,273 using the latest closing price.

Wijkstrom Joakim, the SVP, Chief Marketing Officer of Vanda Pharmaceuticals Inc, sale 9,229 shares at $4.21 during a trade that took place back on Mar 05 ’24, which means that Wijkstrom Joakim is holding 129,789 shares at $38,830 based on the most recent closing price.

Stock Fundamentals for VNDA

Current profitability levels for the company are sitting at:

  • -0.07 for the present operating margin
  • 0.92 for the gross margin

The net margin for Vanda Pharmaceuticals Inc stands at 0.01. The total capital return value is set at -0.02. Equity return is now at value 0.47, with 0.39 for asset returns.

Based on Vanda Pharmaceuticals Inc (VNDA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 1.36. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is 3.96.

Currently, EBITDA for the company is -10.94 million with net debt to EBITDA at 11.12. When we switch over and look at the enterprise to sales, we see a ratio of 0.99. The receivables turnover for the company is 5.64for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.94.


In summary, Vanda Pharmaceuticals Inc (VNDA) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.

Related Posts